On December 12, 2013, Zuckerman testified regarding the type-2 diabetes drug dapagliflozin (Farxiga), saying: "My concern about this drug is that there are just too many unanswered questions – and those unanswered questions are frightening ones. That was true when the FDA rejected this application for approval 2 years ago, and it is still true today." She cited studies that highlighted the risks that the drug poses, as well as methodological concerns such as a lack of diversity in clinical trials.